123

R and D

Since its formation in 2001, Cell>Point has maintained long-term commitments to financially sponsor and support continuing research and development at M. D. Anderson Cancer Center for the EC Technology, In-Situ Hydrogel, N4 Technology, and Dual Agent Technology platforms. Such research and development work is concentrated in the areas of receptor targeting, tissue hypoxia targeting, transcriptional targeting, tumor apoptosis targeting, gene expression targeting, enzymatic targeting, internal radiotherapy and local regional radio/chemotherapy. While development work has proceeded on all five technology platforms, the company has expanded the reach of the sponsored research in respect to the development of the EC Technology platform compounds. The company believes that the versatility and stability of EC Technology will provide significant opportunities to create new imaging and therapeutic agents. Below is the history of EC-G product development.

dev_history

Click on image above to enable full preview